NCT04499768

Brief Summary

To determine the influence of phacoemulsification on choroidal vasculature in patients with diabetic retinopathy (DR) undergoing cataract surgery

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
46

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2018

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2019

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 5, 2020

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2020

Completed
Last Updated

August 5, 2020

Status Verified

August 1, 2020

Enrollment Period

1.4 years

First QC Date

July 30, 2020

Last Update Submit

August 4, 2020

Conditions

Keywords

Diabetic choroidopathyDiabetic retinopathychoroidal vascularity indexchoroidal thickness

Outcome Measures

Primary Outcomes (12)

  • CVI at baseline

    choroidal vascularity index(CVI) was defined as the proportion of vascular area to total circumscribed area.

    CVI was assessed at baseline(within 1 week before surgery)

  • CVI at 1 week postoperatively

    choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area.

    CVI was assessed 1 week after surgery.

  • CVI at 1 month postoperatively

    choroidal vascularity index (CVI) was defined as the proportion of vascular area to total circumscribed area.

    CVI was assessed 1 month after surgery.

  • CVI at 3 months postoperatively

    choroidal vascularity index (CVI)was defined as the proportion of vascular area to total circumscribed area.

    CVI was assessed 3 months after surgery.

  • CT at baseline

    Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.

    CT was assessed at baseline and 1 week, 1 month, 3 month after surgery.

  • CT at 1 week postoperatively

    Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.

    CT was assessed at 1 week after surgery.

  • CT at 1 month postoperatively

    Choroid thickness (CT) was the thickness of the choroidal layer; CT values were obtained with the built-in software of the SS-OCT device.

    CT was assessed at 1 month after surgery.

  • CT at 3 months postoperatively

    Choroid thickness (CT) was the thickness of the choroidal layer, CT values were obtained with the built-in software of the SS-OCT device.

    CT was assessed at 3 months after surgery.

  • VD at baseline

    VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.

    VD of the choriocapillaris was assessed at baseline.

  • VD at 1 week postoperatively

    VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.

    VD of the choriocapillaris was assessed 1 week after surgery.

  • VD at 1 month postoperatively

    VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid.

    VD of the choriocapillaris was assessed 1 month after surgery.

  • VD at 3 months postoperatively

    VD of the choriocapillaris was the vessel density of the choriocapillaris in the choroid

    VD of the choriocapillaris was assessed 3 months after surgery.

Secondary Outcomes (6)

  • IOP at baseline

    IOP was assessed at baseline and 1 week, 1 month, 3 month after surgery.

  • IOP at 1 week postoperatively

    IOP was assessed 1 week after surgery.

  • IOP at 1 month postoperatively

    IOP was assessed 1 month after surgery.

  • IOP at 3 months postoperatively

    IOP was assessed 3 months after surgery.

  • BCVA at baseline

    BCVA was assessed at baseline .

  • +1 more secondary outcomes

Study Arms (2)

control

the age-related cataract patients

DR group

the cataract patients with mild/moderate NPDR

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

23 eyes of 23 cataract patients with mild/moderate NPDR without DME, and 23 age-matched non-diabetic patients

You may qualify if:

  • aged⩾40years; intraocular pressure (IOP) \< 21 mm Hg in both eyes, spherical refractive error\<6 diopters spherical equivalent.

You may not qualify if:

  • previous retinal surgery, glaucoma, uveitis, age-related macular degeneration, arterial or vein occlusions, macular hole, or other ocular diseases that could interfere the CT and/or CVI measurement, severe systemic diseases, such as uncontrolled hypertension, obstructive sleep apnea, etc.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, 200025, China

Location

Related Publications (1)

  • Yao H, Gao S, Liu X, Zhou Y, Cheng Y, Shen X. Choroidal Structural Changes Assessed with Swept-Source Optical Coherence Tomography after Cataract Surgery in Eyes with Diabetic Retinopathy. J Ophthalmol. 2020 Oct 29;2020:5839837. doi: 10.1155/2020/5839837. eCollection 2020.

MeSH Terms

Conditions

Diabetic Retinopathy

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases

Study Officials

  • Xi Shen, PhD

    Shanghai Jiao Tong University School of Medicine

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
chief physician

Study Record Dates

First Submitted

July 30, 2020

First Posted

August 5, 2020

Study Start

June 1, 2018

Primary Completion

October 30, 2019

Study Completion

December 30, 2020

Last Updated

August 5, 2020

Record last verified: 2020-08

Locations